EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Disease models of Leigh syndrome: From yeast to organoids

Marie-Thérèse Henke iD, Alessandro Prigione iD, Markus Schuelke iD

Journal of Inherited Metabolic Disease · 2024-11 · 47 (6) · 1292-1321

DOI: 10.1002/jimd.12804 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 09.10.2024. Verfasst von Marie-Thérèse Henke und 2 weiteren Autor:innen. Beteiligte Einrichtung: NeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Leigh Disease, Disease Models, Animal, Organoids. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HORIZON EUROPE European Research Council, DFG (Deutsche Forschungsgemeinschaft), European Joint Programme for Rare Diseases (EJPRD) supported in Germany by the BMBF (Bundesministerium für Bildung und Forschung).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leigh syndrome (LS) is a severe mitochondrial disease that results from mutations in the nuclear or mitochondrial DNA that impairs cellular respiration and ATP production. Mutations in more than 100 genes have been demonstrated to cause LS. The disease most commonly affects brain development and function, resulting in cognitive and motor impairment. The underlying pathogenesis is challenging to ascertain due to the diverse range of symptoms exhibited by affected individuals and the variability in prognosis. To understand the disease mechanisms of different LS‐causing mutations and to find a suitable treatment, several different model systems have been developed over the last 30 years. This review summarizes the established disease models of LS and their key findings. Smaller organisms such as yeast have been used to study the biochemical properties of causative mutations. Drosophila melanogaster , Danio rerio , and Caenorhabditis elegans have been used to dissect the pathophysiology of the neurological and motor symptoms of LS. Mammalian models, including the widely used Ndufs4 knockout mouse model of complex I deficiency, have been used to study the developmental, cognitive, and motor functions associated with the disease. Finally, cellular models of LS range from immortalized cell lines and trans‐mitochondrial cybrids to more recent model systems such as patient‐derived induced pluripotent stem cells (iPSCs). In particular, iPSCs now allow studying the effects of LS mutations in specialized human cells, including neurons, cardiomyocytes, and even three‐dimensional organoids. These latter models open the possibility of developing high‐throughput drug screens and personalized treatments based on defined disease characteristics captured in the context of a defined cell type. By analyzing all these different model systems, this review aims to provide an overview of past and present means to elucidate the complex pathology of LS. We conclude that each approach is valid for answering specific research questions regarding LS, and that their complementary use could be instrumental in finding treatment solutions for this severe and currently untreatable disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leigh DiseaseDisease Models, AnimalOrganoidsAnimalsHumansDrosophila melanogasterZebrafishCaenorhabditis elegansMiceInduced Pluripotent Stem CellsMutationMitochondriaElectron Transport Complex I

Stichwörter der Autor:innen

Leigh syndromeanimal modelsdisease modelingmitochondrial diseasesorganoidsphenotypingpluripotent stem cells

Substanzen

Electron Transport Complex I

Autor:innen und Institutionen

  • NeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Neuropediatrics, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany.

ORCID-Profile: Marie-Thérèse Henke, Alessandro Prigione, Markus Schuelke

Förderung

  • HORIZON EUROPE European Research Council
  • DFG (Deutsche Forschungsgemeinschaft)
  • European Joint Programme for Rare Diseases (EJPRD) supported in Germany by the BMBF (Bundesministerium für Bildung und Forschung)
  • Foundations MitoHelp, CureMito, and CureATP6
  • Fondation Maladies Rares
  • DFG (Deutsche Forschungsgemeinschaft) under Germany's Excellence Strategy
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Henke, M. T., Prigione, A., & Schuelke, M. (2024). Disease models of Leigh syndrome: From yeast to organoids. Journal of Inherited Metabolic Disease, 47(6), 1292-1321. https://doi.org/10.1002/jimd.12804

Vancouver

Henke MT, Prigione A, Schuelke M. Disease models of Leigh syndrome: From yeast to organoids. Journal of Inherited Metabolic Disease. 2024;47(6):1292-1321. doi:10.1002/jimd.12804

BibTeX
@article{Henke2024,
  author = {Henke, Marie-Thérèse and Prigione, Alessandro and Schuelke, Markus},
  title = {Disease models of Leigh syndrome: From yeast to organoids},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2024},
  volume = {47},
  number = {6},
  pages = {1292--1321},
  doi = {10.1002/jimd.12804}
}
Kostenlos starten →